Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DosEmi: PK-Guided Emicizumab Dosing in Congenital Haemophilia A
2024-515528-35-00Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by University Medical Center Utrecht. Primary endpoint: Proportion of patients without treated bleeds (6 months Bleeding Assessment Phase versus 6 months PK-Guided Dosing Phase). Planned start Jun 2024; status: authorised.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2024-515528-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515528-35-00.